SGLT2 AND DEMENTIA:Recently A study has found that a class of drugs called sodium-glucose cotransporter 2 (SGLT2) inhibitors used to treat type 2 diabetes, might reduce the risk of dementia.The data was analyzed from South Korea and found that individuals taking SGLT2 inhibitors, such as Forxiga and Jardiance, had a 35% lower risk of dementia compared to those taking dipeptidyl peptidase-4 (DPP-4) inhibitors, like Galvus and Invokana. However, further research is needed to establish a causal link. Scientists believe the mechanism could involve reducing inflammation in the brain, lowering the risk of cerebrovascular events, or controlling glucose metabolism. The findings could lead to novel treatment choices for dementia and highlight the repurposing of existing drugs for new indications.Regards,JAKSTAR PHARMA